← board
SCNI
distress 5/10 · elevated risk$0.25+3%today-89% from 52w high
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
0%
Price & events
-69.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.8%
1D
-3.8%
1W
-13.1%
1M
-53.4%
3M
-69.1%
6M
-89.1%
1Y
-94.1%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $3.51B
- Volume
- 84.70K
- 52 Week Range
- $0.24 – $2.32
- Total Shares
- 13.87B
- Float Shares
- 2.81M
- Short %
- 0.52%
- % Held by Insiders
- 10074.84%
- % Held by Institutions
- 1.58%
- RVOL
- 0.14x
- Beta
- 2.11
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.